Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction – the ESC EORP Heart Failure III Registry

Funding Information: This work was supported by the following companies since the start of EORP and for the period of the ESC Heart Failure III study: Abbott Vascular Int. (2018\u20132021), Amgen Cardiovascular (2016\u20132018), AstraZeneca AB (2017\u20132020), Bayer AG (2016\u20132018), Boehringer Ingelheim (2016\u20132019), Bristol Myers Squibb (2017\u20132019), Daichii Sankyo Europe GmbH (2017\u20132020), Edwards Lifesciences (2016\u20132019), Novartis Pharma AG (2018\u20132020), Servier (2015\u20132021), and Vifor (2019\u20132021). Publisher Copyright: © 2024 European Society of Cardiology.